DVT Prevention in Stroke.
The purpose of this review is to discuss the prevention of venous thromboembolism (VTE) in stroke patients. We discuss use of oral anticoagulation and other interventions for the prevention of VTE. A new class of medications, non-vitamin K antagonist oral anticoagulants (NOACs), have been successfully trialed for the prevention of VTE. We review the data and guidance statements for VTE prevention. Warfarin and vitamin K antagonist drugs have been the mainstay of VTE prevention for decades. More recently, NOACs have become available for both stroke and systemic embolism prevention in nonvalvular atrial fibrillation and for VTE treatment or prevention. NOACs have been shown to be at least noninferior for VTE prevention and treatment when compared with warfarin, and have a good safety profile. Other approaches include use of graduated compression stockings, intermittent compression stockings, inferior vena cava filters, and heparins. Selection of the appropriate VTE prophylaxis in stroke patients is important to reduce associated morbidity and mortality.